Table 3 HER2/neu expression in primary USPC cell lines by flow cytometry

From: In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

 

Pertuzumab a

Trastuzumab a

Combination a

 

Sample

(%)

MFI

(%)

MFI

(%)

MFI

P -value b

USPC ARK-1

100

407.5

100

387.4

100

602.7

0.03

USPC ARK-2

100

1366

100

1381

100

1742

0.03

USPC ARK-3

100

607.5

100

679.7

100

751.8

0.04

USPC ARK-4

100

13.2

100

14.8

100

20.6

0.02

USPC ARK-5

100

31.7

100

30.7

100

45.5

0.04

USPC ARK-6

100

30.3

100

31.0

100

50.1

0.03

  1. Abbreviations: MFI=mean fluorescence intensity; USPC=uterine serous papillary adenocarcinoma.
  2. a Dose of pertuzumab and trastuzumab was 2.5 μg ml−1. Total dose of the combination was 2.5 μg ml−1.
  3. b Unpaired samples t-test. Results of a matched flow cytometry experiment are shown and are representative of a minimum of three experiments for each USPC primary cell line. From each primary tumour sample 5000–10 000 gated cells were measured and analysed using a FACScalibur, using cell Quest software, as described in the Methods section.
Back to article page